Disproportionate Short Stature With Ptosis and Valvular Heart Lesions

Heart Valve Disease Awareness Day is February 22 WASHINGTON, Feb. 1, 2024 /PRNewswire/ -- Today officially kicks off Heart Month, a time to raise awareness of heart conditions and heart healthy lifestyles. On February 22, 125 organizations, and countless advocates across the globe will mark Heart Valve Disease Awareness Day by joining together to increase recognition about the valve disease risks and improve detection and treatment. Experience the full interactive Multichannel News Release here: Continue Reading ‘Listen to Your Heart’ this Heart Month to Understand Your Risk for Common, Often Fatal Disease About Heart Valve Disease: Valve disease occurs when one or more of the heart's four valves is defective or damaged, interrupting blood flow and often causing serious complications. More than 11 million Americans have valve disease. More than 25,000 deaths are attributed to valve disease in the U.S. annually. More than 84 million people globally are impacted by valve disease. Symptoms can include lightheadedness, fainting, fluttering heart or chest pain, tiredness, edema, and feeling off in general. Heart murmurs can usually be detected through a simple stethoscope check. If a murmur is detected, additional tests can diagnose valve disease. Valve Disease Risk Factors: Age is the greatest risk factor of valve disease: 1 in 10 people 75 and older are estimated to have moderate or severe heart valve disease Cardiovascular diseases and conditions such as previous heart attack, hypertension, diabetes, and high cholesterol Treatments for certain types of cancer Congenital abnormalities People in communities of color tend to develop heart valve disease at a younger age and should be screened sooner "We know that a simple stethoscope check by a medical professional can save lives, so we're asking everyone to get their heart listened to and encourage their loved ones to do the same," Lindsay Clarke, JD, Senior Vice President of Health Education and Advocacy for the Alliance for Aging Research. About the Alliance for Aging Research The Alliance for Aging Research has served as a trusted source of health information for both consumers and health care professionals on diseases and conditions that disproportionately affect older adults and has led numerous successful advocacy campaigns promoting the health and independence of older adults. Learn more at . To interview someone from the Alliance for Aging Research or one of our 125 partner organizations on the topic of heart valve disease and awareness day activities, email Katie Riley, Vice President of Communications, at [email protected]. SOURCE Alliance for Aging Research

The program will start with 100 general practitioner clinics, with the goal of directing people who need deeper diagnostic workups to schedule an echocardiogram. Eko Health is rolling out its artificial intelligence-equipped stethoscopes to primary care practices across the U.K., through a program led by Imperial College London.  The effort—dubbed TRICORDER, inspired by the Star Trek handheld health scanner, and described as a large-scale deployment—is being funded by the U.K.’s National Institute for Health and Care Research, to assist frontline healthcare workers in catching cases of heart failure, valve disease and atrial fibrillation.  The company’s digital tech platform, known as Sensora in the U.S., recently obtained a U.K. regulatory approval. TRICORDER will start with 100 general practitioner clinics across the country, with the goal of directing people who need deeper diagnostic workups to schedule an echocardiogram. “Heart failure admission alone costs the UK over £2 billion annually, and an unacceptable 80% of these diagnoses are made during emergency admissions,” team leader Nicholas Peters, a professor of cardiology at Imperial College London and the NHS Trust, said in a statement. TRICORDER’s investigators also estimate that applying Eko’s cardiac detection during regularly scheduled primary care visits could save payers £2,400 per patient, or about $3,000 U.S., and help patients skip a potential visit to the emergency room. Eko’s AI approach takes a digital stethoscope with noise-reduction capabilities and combines it with a three-lead electrocardiogram sensor. By analyzing heart sounds and ECG waves, its algorithms aim to detect structural murmurs that could signal a leaky heart valve, as well as spot reductions in the left ventricle’s pumping performance that can be linked to heart failure. The company’s program for detecting heart failure with reduced ejection fraction, or HFrEF, is currently undergoing FDA review, according to Eko, which noted that previous studies pegged the HFrEF algorithm’s sensitivity and specificity as “approaching 80%.” Sensora made its enterprise debut in the U.S. in February, after a heart murmur clearance in July 2022. In September, Eko announced a team-up with Astellas Pharma and Welldoc, with the goal of developing a new heart failure solution integrating Eko’s digital stethoscope with Welldoc’s digital therapeutics.  Astellas has dubbed the proprietary approach Z1608 and said it plans to seek a new FDA clearance for remote patient monitoring and an accompanying smartphone app.

Advanced Manufacturing Minneapolis has announced that Brad S. Sutton, MD, from Boston Scientific will be a  keynote speaker at the event, which includes the Plastec and Medical Design & Manufacturing (MD&M) shows. Sutton will explain how innovations in medical technology are saving ever more lives as well as demonstrably improving the quality of life of patients. In particular, he will discuss the evolution of left atrial appendage closure devices in stroke-prevention procedures, and his personal connection with the technology. Brad. S. Sutton, Boston Scientific. Removing or closing off the left atrial appendage (LAA) has been shown to reduce the risk of stroke and eliminate the need among at-risk populations of taking blood thinners, such as Warfarin. Studies have shown that, among people with atrial fibrillation who don’t have valve disease, most of the blood clots that happen in the left atrium start in the LAA, according to the Cleveland Clinic’s website . “It’s unclear what function, if any, the left atrial appendage performs. Your heart can continue to do its job with a closed left atrial appendage,” it adds. Sutton has participated in clinical trials and helped draft papers involving the Watchman LAA closure device, which is marketed by Boston Scientific. At the Advanced Manufacturing Minneapolis keynote , he will explain how advances such as this are transforming lives around the world. All Advanced Manufacturing Minneapolis visitors are invited to attend the keynote free of charge. The event, which comes to the Minneapolis Convention Center on Oct. 10 and 11, 2023, features more than 500 exhibitors showcasing advances in design and manufacturing, plastics, packaging, and automation for OEMs in the medical device and other sectors. A conference with educational sessions devoted to technological innovations, industry trends, manufacturing logistics, and regulatory developments runs alongside the event. A complete schedule is available online. Advanced Manufacturing Minneapolis is organized by Informa Markets – Engineering, which also publishes PlasticsToday .